Guggenheim analyst Michael Schmidt initiated coverage of Immunome with a Buy rating and $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome to presents preclinical data for IM-3050 at AACR
- Immunome files to sell 2.23M shares of common stock for holders
- Immunome files to sell 2.18M shares of common stock for holders
- Immunome price target raised to $33 from $27 at Wedbush
- Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment
